We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Changes in Eye Tissue May Enable Early Detection of Brain Diseases

By LabMedica International staff writers
Posted on 11 Oct 2016
Print article
Image: An experiment examining retina tissue for mHtt deposition in GFAP-ir astrocytes in R6/2 mouse model of Huntington’s Disease. Green: glial fibrillary acidic protein (GFAP); Red: mutant huntingtin protein (mHtt). (A) A low magnification picture illustrates GFAP-ir astrocytes and mHtt deposits from the retinal wholemount of 12-week-old R6/2 (Huntington’s disease model) mouse. Scale bar = 50 µm. (B) A detailed confocal analysis of GFAP positivity, mHtt immunoreactivity, and DAPI counterstain (blue) revealed no colocalization of GFAP and mHtt. Scale bar = 20 µm (Image courtesy of PLoS One).
Image: An experiment examining retina tissue for mHtt deposition in GFAP-ir astrocytes in R6/2 mouse model of Huntington’s Disease. Green: glial fibrillary acidic protein (GFAP); Red: mutant huntingtin protein (mHtt). (A) A low magnification picture illustrates GFAP-ir astrocytes and mHtt deposits from the retinal wholemount of 12-week-old R6/2 (Huntington’s disease model) mouse. Scale bar = 50 µm. (B) A detailed confocal analysis of GFAP positivity, mHtt immunoreactivity, and DAPI counterstain (blue) revealed no colocalization of GFAP and mHtt. Scale bar = 20 µm (Image courtesy of PLoS One).
Research with mouse models has shown that at least some diseases of the central nervous system (CNS) manifest as pathological changes in the retina of the eye and that these changes may be detected earlier than brain changes. The findings suggest that eye examination could be used for minimally invasive screening for these diseases.

Retina tissue can be considered an integral part of the central nervous system (CNS). During fetal development, it matures from part of the brain and its innervation closely resembles that of the brain. Retinal structure and function can be readily examined with noninvasive or minimally invasive methods, whereas direct brain examination has numerous limitations. If, at least for some brain diseases, the health status of the brain could be indirectly assessed through the eyes, diagnostic screening could become more efficient.

In his PhD project at the University of Eastern Finland at Kuopio (Kuopio, Finland), Dr. Henri Leinonen and colleagues investigated functional abnormalities of the retina using mouse models of human CNS diseases. Electroretinography (ERG) and visual evoked potentials (VEP) were chosen as research techniques, since similar methodology can be applied in both laboratory animals and humans. ERG can precisely track the function of retina using corneal or skin electrodes, whereas VEP measures the function of visual cortex.

These methods were used to test different attributes of vision in 3 distinct genetically engineered mouse models of human CNS diseases. Also, basic life science methods were used to test the correlation between functional abnormalities and the anatomical status of the retina.

Day and color vision -associated retinal dysfunction was found in a mouse model of Huntington´s disease (HD) while the mouse was presymptomatic. Retinal structure remained relatively normal, even in an advanced disease state, although aggregation of toxic mutated huntingtin-protein was widespread in the diseased mouse retina. Although the retinopathy in mice is exaggerated compared to human HD patients, the finding is partly in line with patient data showing impaired color vision but no clear-cut anatomical retinopathy.

In a mouse model of Alzheimer´s disease (AD), the researchers observed abnormality in night vision -associated retinal function. Specifically, rod-mediated inner retinal responses to dim light flashes were faster in diseased mice than in their wild-type controls. The observation may be explained by impaired cholinergic neurotransmission that is also partly causative for the deterioration of memory in AD.

In a mouse model of late infantile neuronal ceroid lipofuscinosis (NCL), a pediatric neurological disease, the researchers described retinal degenerative changes that mimic the characteristic pathology of age-related macular degeneration (AMD). These included impaired function of retinal pigment epithelium and subsequent blindness due to photoreceptor atrophy and death. It has been postulated that the retinal degeneration in human patients progresses similarly.

Adding to the growing body of evidence, the results showed that functional changes of the retina occur in mouse models of three human CNS diseases whose phenotype, age of onset, and pathological mechanism clearly differ from each other. Visual impairment was the fastest progressive symptom in two models tested.

The findings support the idea of eye examinations as potential screening tools for CNS diseases. Development of efficient, safe, and economic screening is imperative since the diagnosis of these diseases is often obtained only in the advanced disease state, when as such satisfactory remedies are poorly effective. Since eye and vision research can be conducted noninvasively, advancement of trials from the preclinical to the clinical phase could be relatively fast.

Dr. Leinonen’s doctoral dissertation, entitled “Electrophysiology of visual pathways as a screening tool for neurodegenerative diseases: evidence from mouse disease models”, is available for download. The findings were published in PLoS One, the Journal of Alzheimer’s Disease, and most recently in the journal Human Molecular Genetics.

Related Links:
University of Eastern Finland

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The proposed self-powered, millifluidic lab-on-a-chip device to determine blood conductivity (Photo courtesy of Advanced Materials/DOI: 10.1002/adma.202403568)

First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring

Metabolic disorders such as diabetes and osteoporosis are rapidly increasing globally, especially in developing countries. Diagnosing these conditions generally requires blood tests; however, in remote... Read more

Molecular Diagnostics

view channel
Image: An illustrated outline of the EarlyTect Bladder Cancer Detection and its clinical applications (Photo courtesy of Promis Diagnostics)

New Urine Test Improves Accuracy for Early Detection of Bladder Cancer in Patients with Hematuria

Blood in the urine, known as hematuria, is often one of the earliest signs of bladder cancer. Although cystoscopy is recommended for patients presenting with both microscopic and gross hematuria, the detection... Read more

Hematology

view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more